|
1
|
Bridgewater J, Galle PR, Khan SA, Llovet
JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J
Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simon D and Balkau B: Diabetes mellitus,
hyperglycaemia and cancer. Diabetes Metab. 36:182–191. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He H, Ke R, Lin H, Ying Y, Liu D and Luo
Z: Metformin, an old drug, brings a new era to cancer therapy.
Cancer J. 21:70–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao
X, Huang S, Wang J, Li Z and Xie K: Metformin potentiates rapamycin
and cisplatin in gastric cancer in mice. Oncotarget. 6:12748–12762.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scotland S, Saland E, Skuli N, de Toni F,
Boutzen H, Micklow E, Sénégas I, Peyraud R, Peyriga L, Théodoro F,
et al: Mitochondrial energetic and AKT status mediate metabolic
effects and apoptosis of metformin in human leukemic cells.
Leukemia. 27:2129–2138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giannoni E, Taddei ML, Morandi A, Comito
G, Calvani M, Bianchini F, Richichi B, Raugei G, Wong N, Tang D, et
al: Targeting stromal-induced pyruvate kinase M2 nuclear
translocation impairs oxphos and prostate cancer metastatic spread.
Oncotarget. 6:24061–24074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujihara S, Kato K, Morishita A, Iwama H,
Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H,
et al: Antidiabetic drug metformin inhibits esophageal
adenocarcinoma cell proliferation in vitro and in vivo. Int J
Oncol. 46:2172–2180. 2015.PubMed/NCBI
|
|
11
|
Hsieh SC, Tsai JP, Yang SF, Tang MJ and
Hsieh YH: Metformin inhibits the invasion of human hepatocellular
carcinoma cells and enhances the chemosensitivity to sorafenib
through a downregulation of the ERK/JNK-mediated NF-κB-dependent
pathway that reduces uPA and MMP-9 expression. Amino Acids.
46:2809–2822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujimori T, Kato K, Fujihara S, Iwama H,
Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H,
et al: Antitumor effect of metformin on cholangiocarcinoma: In
vitro and in vivo studies. Oncol Rep. 34:2987–2996. 2015.PubMed/NCBI
|
|
13
|
Soo JS, Ng CH, Tan SH, Malik RA, Teh YC,
Tan BS, Ho GF, See MH, Taib NA, Yip CH, et al: Metformin synergizes
5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination
therapy through impairing intracellular ATP production and DNA
repair in breast cancer stem cells. Apoptosis. 20:1373–1387. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Honjo S, Ajani JA, Scott AW, Chen Q,
Skinner HD, Stroehlein J, Johnson RL and Song S: Metformin
sensitizes chemotherapy by targeting cancer stem cells and the mTOR
pathway in esophageal cancer. Int J Oncol. 45:567–574.
2014.PubMed/NCBI
|
|
15
|
Ling S, Feng T, Ke Q, Fan N, Li L, Li Z,
Dong C, Wang C, Xu F, Li Y, et al: Metformin inhibits proliferation
and enhances chemosensitivity of intrahepatic cholangiocarcinoma
cell lines. Oncol Rep. 31:2611–2618. 2014.PubMed/NCBI
|
|
16
|
He C, Dong X, Zhai B, Jiang X, Dong D, Li
B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of
hepatocellular carcinoma cells by inhibiting autophagy via the
PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015.PubMed/NCBI
|
|
17
|
Zhu H, Mi Y, Jiang X, Zhou X, Li R, Wei Z,
Jiang H, Lu J and Sun X: Hepatocyte nuclear factor 6 inhibits the
growth and metastasis of cholangiocarcinoma cells by regulating
miR-122. J Cancer Res Clin Oncol. 142:969–980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee EK, Jinesh GG, Laing NM, Choi W,
McConkey DJ and Kamat AM: A Smac mimetic augments the response of
urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol
Ther. 14:812–822. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma Y, Yu WD, Trump DL and Johnson CS:
1,25D3 enhances antitumor activity of gemcitabine and
cisplatin in human bladder cancer models. Cancer. 116:3294–3303.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Ma Y, Jiang H, Zhu H, Liu L, Sun
B, Pan S, Krissansen GW and Sun X: Overexpression of von
Hippel-Lindau protein synergizes with doxorubicin to suppress
hepatocellular carcinoma in mice. J Hepatol. 55:359–368. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blechacz B, Komuta M, Roskams T and Gores
GJ: Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev
Gastroenterol Hepatol. 8:512–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erice O, Merino-Azpitarte M, Arbelaiz A,
Gutierrez-Larranaga M, Jiménez-Agüero R, Perugorria MJ, Bujanda L
and Banales JM: Molecular mechanisms of cholangiocarcinogenesis:
New potential targets for therapy. Curr Drug Targets. 16:12015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nattrass M and Alberti KG: Biguanides.
Diabetologia. 14:71–74. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pryor R and Cabreiro F: Repurposing
metformin: An old drug with new tricks in its binding pockets.
Biochem J. 471:307–322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vakana E, Altman JK and Platanias LC:
Targeting AMPK in the treatment of malignancies. J Cell Biochem.
113:404–409. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hardie DG, Ross FA and Hawley SA:
AMP-activated protein kinase: A target for drugs both ancient and
modern. Chem Biol. 19:1222–1236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang J, Shao SH, Xu ZX, Hennessy B, Ding
Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al:
The energy sensing LKB1-AMPK pathway regulates p27kip1
phosphorylation mediating the decision to enter autophagy or
apoptosis. Nat Cell Biol. 9:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding L, Liang G, Yao Z, Zhang J, Liu R,
Chen H, Zhou Y, Wu H, Yang B and He Q: Metformin prevents cancer
metastasis by inhibiting M2-like polarization of tumor associated
macrophages. Oncotarget. 6:36441–36455. 2015.PubMed/NCBI
|
|
31
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the anti-diabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
34
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chaiteerakij R, Yang JD, Harmsen WS,
Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ,
Roberts RO, Olson JE, et al: Risk factors for intrahepatic
cholangiocarcinoma: Association between metformin use and reduced
cancer risk. Hepatology. 57:648–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang Z, Zhang X, Roberts RO, Roberts LR
and Chaiteerakij R: Metformin does not improve survival of
cholangiocarcinoma patients with diabetes. Hepatology. 63:667–668.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
de Sousa Cavalcante L and Monteiro G:
Gemcitabine: Metabolism and molecular mechanisms of action,
sensitivity and chemoresistance in pancreatic cancer. Eur J
Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
